UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 448

Sortiert nach

Impact of Role Identification Badge Placards on Radiation Oncology Personnel Job Satisfaction and Wellbeing

International journal of radiation oncology, biology, physics, 2024-07, Vol.119 (4), p.e10-e10

2024

Volltextzugriff (PDF)

Weakly supervised pre-training for brain tumor segmentation using principal axis measurements of tumor burden

Frontiers in computer science (Lausanne), 2024-06, Vol.6

2024

Volltextzugriff (PDF)

P057 Measuring adherence to chronic therapies over the first year of treatment with elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis (CF) aged 6–11 years – the RECOVER study

Journal of cystic fibrosis, 2024-06, Vol.23, p.S84-S84

2024

Volltextzugriff (PDF)

EPS4.01 Impact of 18 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6–11 with CF – the RECOVER study

Journal of cystic fibrosis, 2024-06, Vol.23, p.S43-S43

2024

Volltextzugriff (PDF)

WS06.03 Efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis and ELX/TEZ/IVA-responsive, non-F508del genotypes: a phase 3, randomised, placebo-controlled trial

Journal of cystic fibrosis, 2024-06, Vol.23, p.S11-S11

2024

Volltextzugriff (PDF)

WS04.05 Sustained improvement in abdominal symptoms measured by the CFAbd-Score over 2 years of treatment with elexacaftor/tezacaftor/ivacaftor in people with CF aged ≥12 years: results from the RECOVER study

Journal of cystic fibrosis, 2024-06, Vol.23, p.S8-S8

2024

Volltextzugriff (PDF)

P412 “Should I stay or should I go now?” (Transitioning to CF Adult Care)

Journal of cystic fibrosis, 2024-06, Vol.23, p.S194-S194

2024

Volltextzugriff (PDF)

WS13.01 Proteomic analysis of nasal lavage fluid samples in people with cystic fibrosis after one year of treatment with elexacaftor/ivacaftor/tezacaftor – the RECOVER study

Journal of cystic fibrosis, 2024-06, Vol.23, p.S23-S24

2024

Volltextzugriff (PDF)

EPS4.02 Exploring barriers to treatment adherence in people with cystic fibrosis: insights from the RECOVER study at 24 months

Journal of cystic fibrosis, 2024-06, Vol.23, p.S44-S44

2024

Volltextzugriff (PDF)

WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years

Journal of cystic fibrosis, 2024-06, Vol.23, p.S29-S29

2024

Volltextzugriff (PDF)

P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation

Journal of cystic fibrosis, 2024-06, Vol.23, p.S91-S91

2024

Volltextzugriff (PDF)

Selective Hydrogenation of Azobenzene to Hydrazobenzene via Proton-Coupled Electron Transfer from a Polyoxotungstate Cluster

JACS Au, 2024-04, Vol.4 (4), p.1310-1314

2024

Volltextzugriff (PDF)

The synergistic health impacts of exposure to multiple stressors in Tulare County, California

Environmental research, health : ERH, 2024-03, Vol.2 (1), p.15004

2024

Volltextzugriff (PDF)

P 03 - Thymic neoplasms treated with intensity modulated proton therapy

International journal of particle therapy, 2024-03, Vol.11

2024

Volltextzugriff (PDF)

Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues

Journal of cystic fibrosis, 2024-03, Vol.23 (2), p.187-202

2024

Volltextzugriff (PDF)

Characterizing human health damage from ionizing radiation in life cycle assessment

The international journal of life cycle assessment, 2023-12, Vol.28 (12), p.1723-1734

2023

Volltextzugriff (PDF)

196 Airway infection and inflammation in people with cystic fibrosis treated with 1 year of elexacaftor-tezacaftor-ivacaftor—the RECOVER study

Journal of cystic fibrosis, 2023-10, Vol.22, p.S102-S102

2023

Volltextzugriff (PDF)

547 Reduction in abdominal symptoms measured by Cystic Fibrosis Abdomen-score over 6 months of treatment with elexacaftortezacaftor-ivacaftor in children with cystic fibrosis aged 6 to 11: early results from the RECOVER study

Journal of cystic fibrosis, 2023-10, Vol.22, p.S290-S290

2023

Volltextzugriff (PDF)

144 Changes in airway nitric oxide in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—Results from the RECOVER study

Journal of cystic fibrosis, 2023-10, Vol.22, p.S76-S77

2023

Volltextzugriff (PDF)

138 Clinical outcomes in people with cystic fibrosis after 2 years of elexacaftor-tezacaftor-ivacaftor: Results from the RECOVER study

Journal of cystic fibrosis, 2023-10, Vol.22, p.S73-S73

2023

Volltextzugriff (PDF)

485 Measuring adherence to chronic therapies over 2 years of treatment with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis—the RECOVER Study

Journal of cystic fibrosis, 2023-10, Vol.22, p.S255-S255

2023

Volltextzugriff (PDF)

83 Evaluation of ivacaftor and antibiotic therapies on breath biomarkers for Pseudomonas aeruginosa and Staphylococcus aureus in cystic fibrosis

Journal of cystic fibrosis, 2023-10, Vol.22, p.S44-S44

2023

Volltextzugriff (PDF)

142 Elexacaftor-tezacaftor-ivacaftor and spirometry-controlled chest CT scores in children with cystic fibrosis aged 6 to 11

Journal of cystic fibrosis, 2023-10, Vol.22, p.S75-S76

2023

Volltextzugriff (PDF)

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele

American journal of respiratory and critical care medicine, 2023-07, Vol.208 (1), p.59-67

2023

Volltextzugriff (PDF)

P127 Twenty years and counting: longitudinal trends in real-world primary outcomes for people with cystic fibrosis in Ireland and the evolution of a registry

Journal of cystic fibrosis, 2023-06, Vol.22, p.S103-S103

2023

Volltextzugriff (PDF)

1 – 25 von 448

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(426)
Mit Volltextzugriff
(433)

Publikationsform

Sprache

Englisch
(448)
Japanisch
(35)

Erscheinungsjahr

n.n

Thema

Science & Technology
(221)
Life Sciences & Biomedicine
(198)
Environmental Sciences
(131)
Humans
(127)
Environmental Sciences & Ecology
(117)
Technology
(89)
Engineering
(82)
Engineering, Environmental
(75)
Biological And Medical Sciences
(69)
Risk Assessment
(53)
Pollution
(51)
Toxicology
(50)
Female
(49)
Male
(48)
Social Sciences
(46)
Exact Sciences And Technology
(45)
Adult
(44)
Applied Sciences
(43)
Medical Sciences
(43)
Public, Environmental & Occupational Health
(41)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Impact of Role Identification Badge Placards on Radiation Oncology Personnel Job Satisfaction and Wellbeing

Weakly supervised pre-training for brain tumor segmentation using principal axis measurements of tumor burden

P057 Measuring adherence to chronic therapies over the first year of treatment with elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis (CF) aged 6–11 years – the RECOVER study

EPS4.01 Impact of 18 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6–11 with CF – the RECOVER study

WS06.03 Efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis and ELX/TEZ/IVA-responsive, non-F508del genotypes: a phase 3, randomised, placebo-controlled trial

WS04.05 Sustained improvement in abdominal symptoms measured by the CFAbd-Score over 2 years of treatment with elexacaftor/tezacaftor/ivacaftor in people with CF aged ≥12 years: results from the RECOVER study

P412 “Should I stay or should I go now?” (Transitioning to CF Adult Care)

WS13.01 Proteomic analysis of nasal lavage fluid samples in people with cystic fibrosis after one year of treatment with elexacaftor/ivacaftor/tezacaftor – the RECOVER study

EPS4.02 Exploring barriers to treatment adherence in people with cystic fibrosis: insights from the RECOVER study at 24 months

WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years

P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation

Selective Hydrogenation of Azobenzene to Hydrazobenzene via Proton-Coupled Electron Transfer from a Polyoxotungstate Cluster

The synergistic health impacts of exposure to multiple stressors in Tulare County, California

P 03 - Thymic neoplasms treated with intensity modulated proton therapy

Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues

Characterizing human health damage from ionizing radiation in life cycle assessment

196 Airway infection and inflammation in people with cystic fibrosis treated with 1 year of elexacaftor-tezacaftor-ivacaftor—the RECOVER study

547 Reduction in abdominal symptoms measured by Cystic Fibrosis Abdomen-score over 6 months of treatment with elexacaftortezacaftor-ivacaftor in children with cystic fibrosis aged 6 to 11: early results from the RECOVER study

144 Changes in airway nitric oxide in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—Results from the RECOVER study

138 Clinical outcomes in people with cystic fibrosis after 2 years of elexacaftor-tezacaftor-ivacaftor: Results from the RECOVER study

485 Measuring adherence to chronic therapies over 2 years of treatment with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis—the RECOVER Study

83 Evaluation of ivacaftor and antibiotic therapies on breath biomarkers for Pseudomonas aeruginosa and Staphylococcus aureus in cystic fibrosis

142 Elexacaftor-tezacaftor-ivacaftor and spirometry-controlled chest CT scores in children with cystic fibrosis aged 6 to 11

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele

P127 Twenty years and counting: longitudinal trends in real-world primary outcomes for people with cystic fibrosis in Ireland and the evolution of a registry

Suchergebnisse filtern